Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAetna esophageal pH monitoring Coverage & Prior Au…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0667

    Esophageal and Airway pH Monitoring

    Customize your policy alerts

    Sign up for Aetna Policy 0667 alerts

    Get alerted when Policy 0667 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage rules for esophageal and airway pH monitoring technologies (catheter-based, catheter-free Bravo, multichannel intraluminal impedance variants) and indications for adults and children, specifying medically necessary versus experimental/investigational uses for Aetna members.

    Policy Summary
    PayerAetna
    PolicyEsophageal and Airway pH Monitoring
    Policy CodePolicy 0667
    Change TypeNo material change
    Effective DateJul 22, 2003
    Last ReviewSep 25, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain and document prior authorization and pre-test medication status (including PPI trial or withholding) and the clinical indication to support coverage.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7medically necessary indications
    InvestigationalMII-pH investigational for GERD
    40Lyon physiologic threshold
    80Lyon pathologic threshold
    07/22/2003effective date
    09/25/2023last review

    Coverage criteria — esophageal and airway pH monitoring

    inv-01: Medically Necessary: Esophageal pH monitoring

    Esophageal pH monitoring is considered medically necessary when any one of the following indications is met:

    Medically necessary indications for esophageal pH monitoring: 1) To detect refractory reflux in members with chest pain after cardiac evaluation using a symptom–reflux association scheme, preferably the symptom association probability calculation (pH study done after a trial of proton pump inhibitor [PPI] therapy for at least 4 weeks); OR 2) To document abnormal esophageal acid exposure in an endoscopy-negative member being considered for surgical anti-reflux repair (pH study done after withholding anti-secretory drugs >1 week); OR 3) To document concomitant gastro-esophageal reflux disease (GERD) in an adult-onset, non-allergic asthmatic suspected of having reflux-induced asthma (pH study done after withholding anti-secretory drugs >1 week) — note a positive test does not prove causality; OR 4) To evaluate suspected otolaryngologic manifestations (chronic cough, laryngitis, pharyngitis) of GERD after symptoms have failed to respond to at least 4 weeks of PPI therapy (pH study done while continuing anti-secretory regimen to document adequacy of therapy); OR 5) To evaluate vomiting in infants up to 3 months of age; OR 6) To evaluate members after anti-reflux surgery who are suspected to have ongoing abnormal reflux (pH study after withholding anti-secretory drugs >1 week); OR 7) To evaluate members with normal or equivocal endoscopy and reflux symptoms refractory to PPI therapy (pH study after withholding anti-secretory drugs >=1 week if confirming excessive acid exposure or while taking anti-secretory regimen if scoring symptom–reflux correlation).any

    inv-02: Bravo pH monitoring

    The capsule (Bravo) system may be used as an alternative to catheter-based monitoring except where specifically contraindicated:

    Bravo capsule acceptance: The disposable wireless capsule pH monitor (Bravo) is considered an acceptable alternative to standard catheter-based ambulatory pH monitoring for the medically necessary indications listed for esophageal pH monitoring, except it is not considered acceptable for evaluation of vomiting in infants (Bravo not approved for this age group).all

    inv-03: MII and combined testing

    Coverage stance for multichannel intraluminal impedance (MII) and combined testing modalities:

    MII and combined testing indications: 1) MII testing is covered for evaluation of GERD in children and adolescents (≤18 years); OR 2) MII combined with esophageal manometry (MII-EM) is covered for evaluation of refractory dysphagia, heartburn/regurgitation, unexplained non-cardiac chest pain, and pre-operative evaluation before anti-reflux surgery; OR 3) MII combined with pH testing (MII-pH) is covered for evaluation of individuals with incomplete or no response to PPI therapy who have normal endoscopic findings and for evaluation of atypical GER symptoms (eg, chronic cough).any

    MII is considered investigational for other indications (eg, achalasia, laryngo-pharyngeal reflux).

    inv-04: Experimental and Investigational

    The following devices and test applications are considered experimental or investigational and are not covered because effectiveness has not been established:

    Experimental or investigational: 1) Bravo pH Monitoring System for evaluating vomiting in infants (not approved for this age group); OR 2) Esophageal pH recording for other indications including detecting/verifying reflux esophagitis in adults, evaluation of alkaline reflux, identifying eosinophilic esophagitis in children with esophageal atresia, and titrating PPI dosing for Barrett's esophagus; OR 3) Airway pH monitoring for detection of laryngopharyngeal reflux and other indications; OR 4) Pharyngeal (oropharyngeal) pH monitoring for diagnosis of extra-esophageal reflux disease as a standalone test; OR 5) Measurement of airway impedance for diagnosis of gastroesophageal reflux or aspiration and prediction of extraesophageal airway inflammation — all considered experimental/investigational due to insufficient evidence of effectiveness.any

    inv-05: Coverage rationale / investigational stance

    Summary coverage rationale and investigational designation from guideline and technology assessments:

    Investigational designation: Multichannel intraluminal impedance in combination with pH monitoring for evaluation of GERD is considered investigational/experimental because there is inadequate evidence in the peer-reviewed published clinical literature regarding its effectiveness.

    Statement reflects summaries from AGA, AHRQ, and Centre for Evidence-based Purchasing assessments.

    Guideline uncertainty: Professional society assessments and technology reviews concluded that evidence is inconclusive or of generally poor quality, with few high-quality outcome trials and insufficient data to make firm recommendations for many adult GERD indications involving impedance monitoring.

    References include AGA technical review, AHRQ assessment, and SAGES guideline summaries.

    inv-06: Indications for MII-pH and Manometry

    MII-pH and manometry are covered when testing is indicated to diagnose or further characterize reflux in these clinical scenarios:

    Indications for MII-pH and MII-EM: Patients with incomplete or no response to PPI therapy; patients with atypical (extra-esophageal) GERD symptoms such as chronic cough; preoperative evaluation prior to anti-reflux surgery; quantification and characterization of GER when endoscopy is normal and clinical uncertainty exists.

    Whether testing is performed on or off PPI therapy depends on the indication: for refractory symptoms administer high-dose PPI prior to testing; to clarify if GERD is the cause of symptoms, perform testing off PPIs.

    inv-07: Utility versus conventional pH monitoring

    Comparative rationale: when impedance adds diagnostic value compared with conventional pH monitoring:

    Comparative utility: MII-pH is more sensitive than pH catheter alone for detecting acid and weakly acidic reflux; reported sensitivity of a pH catheter for acid reflux is approximately 58% versus MII-pH and about 28% for weak acid reflux. MII-pH allows assessment while patients remain on PPI therapy to detect non-acid reflux and may increase diagnostic yield in certain patients (eg, those on acid suppression).

    Clinical impact and effects on outcomes remain limited by the quality of available studies.

    inv-08: Airway impedance (investigational)

    Airway impedance measurement at the larynx is considered investigational:

    Airway impedance (investigational): Catheter-based airway impedance measurement placed at the posterior larynx to assess extra-esophageal disease is investigational. Preliminary prospective data show no significant correlation between airway impedance and standardized reflux finding scores or strong correlation with esophageal impedance; associations with aspiration on swallow studies were observed in small cohorts, but clinical utility and validated diagnostic thresholds are not established.

    Further validation in larger cohorts and correlation with clinical outcomes are required before routine clinical use.

    The disposable capsule pH monitor (Bravo pH Monitoring System) is considered an acceptable alternative to standard catheter-based ambulatory pH monitoring for the medically necessary indications in this policy except for evaluating vomiting in infants, because the Bravo system has not been approved for use in that age group and therefore is not acceptable for infant vomiting assessment.

    Multichannel intraluminal impedance combined with pH monitoring (MII-pH) is described in this policy as investigational/experimental for routine evaluation of adult GERD because the peer‑reviewed literature and technology assessments show inadequate high‑quality evidence for improved clinical outcomes; professional society reviews and technology assessments have found the evidence inconclusive and lacking rigorous outcome trials.

    Interpretation of impedance and combined MII-pH testing must consider the testing context, including whether the study is performed on or off proton pump inhibitor (PPI) therapy. For refractory GERD symptoms clinicians often administer high‑dose PPI (e.g., twice daily) for at least 1 week before MII-pH to detect weakly acidic reflux, whereas when the causal role of reflux is uncertain testing is typically performed off PPIs to maximize detection. Documentation of PPI status and the clinical indication should accompany testing because results and clinical interpretation differ by therapy status.

    Typical indications for esophageal pH recording include: verification of abnormal esophageal acid exposure in endoscopy‑negative patients being considered for anti‑reflux surgery; evaluation of suspected reflux‑related extra‑esophageal symptoms (for example chronic cough, laryngitis, or chest pain) after an appropriate PPI trial; documentation of concomitant GERD in adult‑onset non‑allergic asthma when testing is performed off anti‑secretory drugs; assessment of ongoing reflux after anti‑reflux surgery; and evaluation of infants with vomiting up to 3 months of age (with modality‑specific exclusions such as Bravo not approved for infant vomiting). pH recording is also used for detection/verification of reflux esophagitis and other diagnostic questions listed in the policy, though some of these specific uses are considered investigational.

    Pharyngeal (oropharyngeal) pH monitoring has important limitations and may substantially over‑estimate supra‑esophageal gastric reflux when used alone. Studies comparing Dx‑pH/OP pH monitoring with concurrent esophageal MII‑pH show many oropharyngeal pH events are not temporally correlated with esophageal reflux events, and the use of extended or alternative pH thresholds increases detected OP events while the majority remain unrelated to GER episodes, suggesting potential artifact and over‑estimation risk.

    The intended role of MII‑pH testing is to characterize reflux when symptoms persist despite therapy or when it is clinically necessary to distinguish acid versus non‑acid (weakly acidic) reflux. MII‑pH can detect reflux independent of pH and identify weak acid reflux (pH 4–7), which is useful in patients with incomplete or no response to PPI therapy and in evaluation of atypical extra‑esophageal symptoms; however, routine use without appropriate indication is not supported by the evidence and MII‑pH is considered investigational for many adult GERD indications.

    Coding and thresholds

    Covered CPT Codes when criteria metCPTCovered
    91034Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis and interpretation.
    91035with mucosal attached telemetry pH electrode placement, recording, analysis and interpretation.
    91037Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation.
    91038Esophageal function test, gastroesophageal reflux test with nasal catheter intraluminal impedance electrode(s) placement, recording, analysis and interpretation; prolonged (greater than 1 hour, up to 24 hours).
    91010Esophageal motility (manometric study of the esophagus and/or gastroesophageal junction) study with interpretation and report.
    ICD-10 codes covered when selection criteria are metICD-10
    K21.00 - K21.9Gastro-esophageal reflux disease.
    R05.1 - R05.9Cough.
    R07.9Chest pain, unspecified.
    J45.20 - J45.50Intermittent and persistent asthma, uncomplicated.
    ICD-10 codes not covered for CPB indications (examples)ICD-10Not Covered
    K22.70 - K22.719Barrett's esophagus.
    P92.01 - P92.09Bilious and other vomiting in newborn.
    Q39.0 - Q39.1Atresia of esophagus [in children].
    R11.10 - R11.14Vomiting.
    Lyon consensus reflux event thresholds — physiologic / pathologic numeric thresholds
    Lyon physiologic thresholdPhysiologic reflux: 40 or fewer reflux events on impedance monitoring
    Lyon pathologic thresholdPathologic reflux: greater than 80 reflux events on impedance monitoring
    Clinical implicationThresholds allow interpretation of reflux burden independent of pH, supporting testing on PPI when indicated

    Provider actions, prior authorization & documentation

    Prior Authorization

    Obtain authorization for covered CPTs when criteria are met

    CPT codes for esophageal pH and impedance testing (e.g., 91010, 91034, 91035, 91037, 91038) are covered only when the patient's clinical presentation meets the policy's selection criteria; providers should obtain prior authorization when submitting these codes with corresponding indications.

    • Covered CPTs listed in policy: 91010, 91034, 91035, 91037, 91038.
    • Authorization should be tied to documentation that the indication meets the policy's medically necessary criteria.
    Prior Authorization

    Prior authorization may be affected by investigational MII‑pH status

    Because multichannel intraluminal impedance combined with pH monitoring (MII-pH) is described as investigational/experimental for certain GERD indications, prior authorization requests for MII‑pH for those indications may be denied or require additional review.

    • Policy states MII-pH is considered investigational/experimental due to inadequate evidence for some GERD indications.

    Background and evidence summary

    Esophageal pH monitoring quantifies esophageal acid exposure and provides measures of symptom–reflux correlation but does not by itself prove causality between reflux events and symptoms. Standard catheter-based ambulatory pH monitoring typically records for 24–48 hours; the Bravo wireless capsule is an endoscopically attached, catheter‑free alternative that transmits pH data for multiple days and may be better tolerated. Clinically, a therapeutic trial of a proton pump inhibitor (PPI) is commonly used prior to testing in several indications to assess symptom response, and pH testing should be interpreted in the context of pre‑test medication status.

    Definitions and test descriptions

    Bravo pH Monitoring System — wireless capsule description and operational notes
    Device descriptionDisposable wireless capsule (Bravo) attached endoscopically to the lower esophagus that transmits pH data to an external data logger and is later sloughed and passed
    Placement and durationEndoscopically pinned to the lower esophagus; records pH data over several days while worn with an external recorder
    Tolerability and alternativesCatheter-free approach improves patient tolerability compared with nasogastric catheter-based monitoring but may be unsuitable for some patients (e.g., pacemaker) per NICE assessment
    Multichannel intraluminal impedance (MII) — technology characterization and combinations
    Technology functionMultichannel intraluminal impedance (MII) detects intraluminal bolus movement within the esophagus independent of pH
    Common combinations

    Policy history and review dates

    2003-07-22effective

    Policy became effective.

    2023-09-25last_reviewLatest

    Policy was last reviewed and updated.

    2024-07-25next_review

    Next scheduled policy review date.

    Policy Summary
    PayerAetna
    PolicyEsophageal and Airway pH Monitoring
    Policy CodePolicy 0667
    Change TypeNo material change
    Effective DateJul 22, 2003
    Last ReviewSep 25, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain and document prior authorization and pre-test medication status (including PPI trial or withholding) and the clinical indication to support coverage.
    SourceLink
    On This Page
    Coverage criteria — esophageal and airway pH monitoringCoding and thresholdsProvider actions, prior authorization & documentationBackground and evidence summaryDefinitions and test descriptionsPolicy history and review dates
  1. Payer prior authorization decisions may reflect this investigational designation.
  2. Prior Authorization

    Authorization must reflect indication and PPI on/off status

    Prior authorization and claim submission should explicitly state the clinical indication for testing and whether the study will be performed on or off PPI therapy, since the appropriate testing context depends on the indication.

    • Decision to perform MII-pH on or off PPI therapy should be based on the underlying indication (e.g., refractory symptoms vs diagnostic clarification).
    • Policy notes testing intent (detect weakly acidic reflux vs optimize detection) varies with PPI status.
    Note

    Follow administrative prior authorization processes

    The policy does not list a discrete set of CPT/HCPCS codes that universally require prior authorization; providers should follow plan-specific administrative prior authorization processes and submit clinical justification tied to the policy criteria.

    • Chunks do not specify particular CPT/HCPCS codes that always require prior authorization.
    • Use clinical documentation matched to the policy's medically necessary indications when requesting authorization.
    Step Therapy

    Document PPI trial of at least 4 weeks before testing when indicated

    For several medically necessary indications the policy expects a therapeutic trial of a proton pump inhibitor (PPI) for at least 4 weeks before pH testing to assess symptom response.

    • Examples: chest pain after cardiac evaluation and otolaryngologic manifestations should have PPI trial ≥4 weeks prior to pH study when indicated.
    • Therapeutic PPI trial is a commonly used clinical alternative and is referenced as part of testing indications.
    Step Therapy

    Consider empiric anti-reflux therapy before advanced testing

    Empiric anti-reflux therapy (for example, PPI therapy) is described in the policy as a common initial clinical approach for suspected reflux-related symptoms and should be considered before advanced testing when clinically appropriate.

    • Xu et al (2014) note empirical therapy is recommended as an initial approach for GER-induced chronic cough.
    • MII-pH is discussed as a diagnostic tool after empiric therapy when symptoms persist.
    Note

    Use MII‑pH when symptoms persist after empiric therapy

    When symptoms persist after empiric therapy (for example inadequate response to PPI), MII‑pH testing can be used to characterize acid versus non‑acid reflux and help guide further management.

    • Policy indicates MII‑pH is intended to determine whether non‑acid reflux is causing ongoing symptoms in patients with incomplete or no response to PPIs.
    • Use MII‑pH to characterize reflux when empiric therapy response is inadequate.
    Note
    Documentation Required

    Document pre-test PPI/anti-secretory status and symptom timing

    Document the patient's pre-test medication status (on or withheld anti-secretory drugs) and symptom pattern relative to the test, since several medically necessary indications require testing either after a PPI trial or after withholding anti‑secretory drugs for >1 week.

    • Examples in policy: studies to confirm excessive acid exposure are done after withholding anti-secretory drugs ≥1 week; refractory-symptom testing may be done while continuing anti-secretory regimen.
    • Symptom–reflux association documentation (e.g., symptom association probability) is preferred for some indications.
    Documentation Required

    Include concurrent endoscopy, histology, and atopy data in pediatric EoE/EA reports

    In pediatric evaluations for esophageal atresia or eosinophilic esophagitis, document concurrent diagnostic testing (upper endoscopy with histology) and relevant findings such as atopy or peripheral eosinophilia when reporting pH‑impedance results.

    • Studies cited required all patients to undergo upper GI endoscopy and pH‑impedance monitoring.
    • Policy notes that atopy and peripheral eosinophilia were predictive factors and should be documented.
    Documentation Required

    Record test context: indication and on/off PPI status

    Always state in the record whether MII‑pH testing was performed on or off PPI therapy and the clinical indication for the test (e.g., refractory GERD symptoms, atypical symptoms, preoperative evaluation).

    • Policy and UpToDate guidance specify that the decision to test on or off PPIs depends on the indication and affects interpretation.
    • Documentation of test context supports appropriate interpretation and authorization.
    Documentation Required

    Include policy history/administrative references in authorization documentation

    Document the policy version, review dates, and administrative links in the patient's authorization or chart note when relevant; the policy history and administrative resources are provided in the bulletin.

    • Policy history includes last review date 09/25/2023, effective date 07/22/2003, and next review 07/25/2024.
    • Administrative links (definitions, review history) are available via the policy bulletin.
    Denial Risk

    Investigational MII‑pH indications may be denied without justification

    Claims for MII‑pH testing for GERD indications described as investigational/experimental in the policy are at risk for denial; include supporting clinical justification and reference to specific medically necessary criteria when requesting coverage.

    • Policy states MII‑pH is investigational/experimental for evaluation of GERD where evidence is inadequate.
    • Prior authorization requests for these indications may be denied without strong supporting documentation.
    Denial Risk

    Document indication plus PPI on/off status to avoid denial

    Failure to document the clinical indication and whether testing was performed on or off PPI therapy may result in inappropriate interpretation or denial; record both the indication and PPI status in the preauthorization and operative/report notes.

    • Policy emphasizes the decision to perform testing on or off PPI therapy should be indication‑driven.
    • Documenting PPI status and indication is necessary for correct test interpretation and coverage decisions.
    Note
    Note
    MII is performed combined with manometry (MII-EM) to assess pressures and bolus transit, or combined with pH (MII-pH) to detect acid and non-acid reflux
    Clinical intentDesigned to characterize bolus movement, identify non-acid reflux, and assess esophageal function without radiation
    MII-pH — combined impedance and pH monitoring definition and capabilities
    DefinitionCombined multichannel intraluminal impedance and pH monitoring (MII-pH) records bolus movement (impedance) and acidity (pH) to detect acid and non-acid reflux and correlate events with symptoms
    Clinical capabilitiesDetects acid and weakly acidic (pH 4–7) reflux, distinguishes liquid vs gas reflux, and enables symptom–reflux association analysis
    Use on/off PPIDecision to perform MII-pH on or off PPI depends on indication: perform on PPI to detect non-acid reflux in refractory patients or off PPI when clarifying if GERD causes symptoms
    EFT / Manometry + MII — esophageal function testing combining impedance and manometry
    Test compositionEsophageal function testing (EFT) combining multichannel intraluminal impedance with pressure manometry (MII-EM) assesses both bolus transit and esophageal motility
    IndicationsIndicated for evaluation of dysphagia, noncardiac chest pain, heartburn/regurgitation, and preoperative assessment before antireflux surgery
    Clinical advantageProvides simultaneous information about pressures and bolus transit to evaluate esophageal function without radiation
    MII-pH (alternate chunk) — combined testing detecting reflux above LES irrespective of pH
    Core definitionMII-pH measures changes in electrical conductivity across multiple probe points combined with pH to detect reflux of any material above the LES irrespective of pH
    Detects weak acid refluxMII-pH can identify weakly acidic reflux (pH 4–7) and quantify reflux burden independent of acidity
    Preoperative and refractory useUseful for preoperative evaluation and for patients with incomplete/no response to PPI therapy where non-acid reflux is suspected
    Lyon consensus thresholds — physiologic <=40 and pathologic >80 reflux events definitions
    Physiologic cutoffPhysiologic reflux is defined as 40 or fewer reflux events on impedance monitoring
    Pathologic cutoffPathologic reflux is defined as greater than 80 reflux events on impedance monitoring
    Interpretive noteThese numeric thresholds permit interpretation of reflux burden independent of pH and support testing while on PPI when clinically appropriate
    Airway impedance — investigational catheter-based impedance measurement at posterior larynx
    Technique descriptionAirway impedance uses an impedance catheter placed on the posterior larynx to obtain measurements intended to assess extra‑esophageal disease or aspiration
    Current evidencePreliminary prospective data show no significant correlation with reflux finding scores or esophageal impedance and variable associations with aspiration and PPI use
    Coverage statusConsidered investigational because clinical utility and correlation with established measures are not yet established